Menu Search
Equities

Bayer AG

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BAYN:VIE

Bayer AG

Actions
  • Price (--)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta1.0513
--
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bayer AG is a German-based life science company. The Company's segments are Crop Science, Pharmaceuticals and Consumer Health. The Crop Science segment focuses on development, production and marketing of products in seeds and plant traits, crop protection, digital solutions and customer services to promote sustainable agriculture. The Pharmaceuticals segment focuses on prescription products, especially for cardiology and women's healthcare and specialty therapeutics focused on the areas of cardiology, oncology, hematology and ophthalmology, as well as gene therapy and others. The Consumer Health segment develops, produces and markets nonprescription over-the-counter medicines for self-medication. Its Consumer Health segment portfolio consists of products in dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories.

  • Revenue in EUR (TTM)46.58bn
  • Net income in EUR-3.25bn
  • Incorporated1952
  • Employees90.89k
  • Location
    Bayer AGKaiser-Wilhelm-Allee 1LEVERKUSEN 51373GermanyDEU
  • Phone+49 214301
  • Fax+49 2 143066328
  • Websitehttps://www.bayer.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		BAYX.N:GER since
announced		Transaction
value
HiDoc Technologies GmbHAnnounced11 Dec 202411 Dec 2024Announced36.37%--
Data delayed at least 15 minutes, as of Jul 18 2025 16:42 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.